JP2019529371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529371A5 JP2019529371A5 JP2019511517A JP2019511517A JP2019529371A5 JP 2019529371 A5 JP2019529371 A5 JP 2019529371A5 JP 2019511517 A JP2019511517 A JP 2019511517A JP 2019511517 A JP2019511517 A JP 2019511517A JP 2019529371 A5 JP2019529371 A5 JP 2019529371A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- seq
- antibody
- antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000027455 binding Effects 0.000 claims description 43
- 239000012634 fragment Substances 0.000 claims description 32
- 239000000427 antigen Substances 0.000 claims description 31
- 102000036639 antigens Human genes 0.000 claims description 31
- 108091007433 antigens Proteins 0.000 claims description 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 102100038367 Gremlin-1 Human genes 0.000 claims description 24
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 claims description 24
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 18
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 4
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- 238000010494 dissociation reaction Methods 0.000 claims description 4
- 230000005593 dissociations Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 230000009870 specific binding Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 238000012286 ELISA Assay Methods 0.000 claims description 2
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims description 2
- 239000000480 calcium channel blocker Substances 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 2
- 230000003177 cardiotonic effect Effects 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 125000003147 glycosyl group Chemical group 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 150000003815 prostacyclins Chemical class 0.000 claims description 2
- 210000001147 pulmonary artery Anatomy 0.000 claims description 2
- 210000005241 right ventricle Anatomy 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000008719 thickening Effects 0.000 claims description 2
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662380562P | 2016-08-29 | 2016-08-29 | |
| US62/380,562 | 2016-08-29 | ||
| PCT/US2017/048137 WO2018044640A1 (en) | 2016-08-29 | 2017-08-23 | Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019529371A JP2019529371A (ja) | 2019-10-17 |
| JP2019529371A5 true JP2019529371A5 (enExample) | 2020-10-01 |
Family
ID=59791160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511517A Pending JP2019529371A (ja) | 2016-08-29 | 2017-08-23 | 肺動脈性肺高血圧を処置するための抗グレムリン−１（ｇｒｅｍ１）抗体およびその使用の方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180057580A1 (enExample) |
| EP (1) | EP3504238A1 (enExample) |
| JP (1) | JP2019529371A (enExample) |
| KR (1) | KR20190040320A (enExample) |
| CN (1) | CN109641954A (enExample) |
| AU (1) | AU2017320989A1 (enExample) |
| CA (1) | CA3031783A1 (enExample) |
| EA (1) | EA201990613A1 (enExample) |
| IL (1) | IL264309A (enExample) |
| MA (1) | MA46046A (enExample) |
| MX (1) | MX2019002382A (enExample) |
| WO (1) | WO2018044640A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11680101B2 (en) | 2017-01-27 | 2023-06-20 | Kymab Limited | Anti-OPG antibodies |
| MX2022016403A (es) | 2020-06-18 | 2023-04-11 | Regeneron Pharma | Formulaciones de anticuerpo de activina a y métodos para utilizarlas. |
| JP2024504124A (ja) * | 2021-01-18 | 2024-01-30 | スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド | 新規の抗グレムリン１抗体 |
| AU2023258146A1 (en) * | 2022-04-20 | 2024-09-05 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
| WO2024258870A2 (en) | 2023-06-12 | 2024-12-19 | Amgen Inc. | Lymphotoxin beta receptor agonist binding proteins |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
| US7420040B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US9610356B2 (en) * | 2011-12-12 | 2017-04-04 | Pieris Pharmaceutical GmbH | Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation |
| JP6400479B2 (ja) * | 2012-10-29 | 2018-10-03 | 株式会社カルディオ | 肺疾患特異的治療剤 |
| KR20150129718A (ko) * | 2013-03-14 | 2015-11-20 | 리제너론 파아마슈티컬스, 인크. | Ｇｒｅｍ 1에 대한 인간 항체 |
-
2017
- 2017-08-23 WO PCT/US2017/048137 patent/WO2018044640A1/en not_active Ceased
- 2017-08-23 MX MX2019002382A patent/MX2019002382A/es unknown
- 2017-08-23 CA CA3031783A patent/CA3031783A1/en not_active Abandoned
- 2017-08-23 EA EA201990613A patent/EA201990613A1/ru unknown
- 2017-08-23 CN CN201780052609.5A patent/CN109641954A/zh active Pending
- 2017-08-23 US US15/684,073 patent/US20180057580A1/en not_active Abandoned
- 2017-08-23 AU AU2017320989A patent/AU2017320989A1/en not_active Abandoned
- 2017-08-23 JP JP2019511517A patent/JP2019529371A/ja active Pending
- 2017-08-23 MA MA046046A patent/MA46046A/fr unknown
- 2017-08-23 EP EP17761986.3A patent/EP3504238A1/en not_active Withdrawn
- 2017-08-23 KR KR1020197008656A patent/KR20190040320A/ko not_active Ceased
-
2019
- 2019-01-17 IL IL264309A patent/IL264309A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529371A5 (enExample) | ||
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| JP2016519650A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| JP2017536414A5 (enExample) | ||
| JP2012513193A5 (enExample) | ||
| WO2006055809A3 (en) | Antibodies against vascular endothelial growth factor receptor-1 | |
| AR069062A1 (es) | Anticuerpo anti-hepcidina | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| PE20070317A1 (es) | Agentes de union a esclerostina o fragmentos de esclerostina | |
| RU2013155906A (ru) | Антитела анти-angptl3 и их применение | |
| RU2016138744A (ru) | Антитела, фармацевтические композиции и их применения | |
| NZ610734A (en) | Human antibodies to the glucagon receptor | |
| IL272674B2 (en) | Preparations for use in the treatment or prevention of graft-versus-graft disease or disseminated intravascular hemorrhage or veno-occlusive disease associated with hematopoietic stem cell transplantation | |
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| NZ600768A (en) | Human antibodies to human angiopoietin-like protein 4 | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| NZ706986A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| AR098663A1 (es) | Anticuerpos multifuncionales que se unen a egfr y met | |
| EA201290525A1 (ru) | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| JP2018535948A5 (enExample) | ||
| CN102027015A (zh) | 抗cxcr4抗体 | |
| JP2020511946A5 (enExample) |